Troponin-T is preferable to CPK-MB in the diagnosis of acute myocardial infarction (MI) in all of the following situations except:
First, I need to recall the differences between Troponin-T and CPK-MB. Troponin is more specific for cardiac muscle, right? It rises earlier and stays elevated longer. CPK-MB is also cardiac-specific but has a shorter window. So when would Troponin-T not be better?
Possible scenarios where CPK-MB might be better: maybe in cases of reinfarction where troponin levels are still elevated from a previous MI. Because troponin has a longer half-life, it might not detect a new MI if there's residual troponin from an old one. CPK-MB clears faster, so a rise in CPK-MB would indicate a new event.
Another situation could be in patients with chronic kidney disease, where troponin might be elevated even without MI due to renal dysfunction. But I'm not sure if that's a standard exception. Alternatively, maybe in the early stages before troponin rises, but CPK-MB comes up faster. Wait, actually, troponin rises faster than CPK-MB. So that's not it.
Wait, the question is about when Troponin-T is not preferable. So the correct answer would be a situation where CPK-MB is better. The key point is that in reinfarction, since troponin stays elevated for days, you can't tell if a new MI is happening. CPK-MB, which peaks in 24 hours and returns faster, would show a rise again, indicating a new event. So in the setting of reinfarction, CPK-MB is better because it's more dynamic.
Other situations where CPK-MB might be preferred: maybe in patients with certain muscle diseases where troponin could be falsely elevated? Not sure. But the main high-yield fact here is reinfarction. So the exception is when there's a need to detect a reinfarction, where CPK-MB is more useful than Troponin-T. So the correct answer would be an option stating that, and the other options would be situations where Troponin-T is better.
Now, the user's correct answer is missing, but based on standard knowledge, the exception is reinfarction. So if an option says "Reinfarction" or "Recurrent MI," that's the answer. The other options would be scenarios where Troponin-T is better, like in early detection, higher specificity, or in cases of renal failure where troponin is already elevated, but I think the main one is reinfarction.
**Core Concept**
Troponin-T and CPK-MB are biomarkers for myocardial injury. Troponin-T has higher sensitivity/specificity, rises earlier, and remains elevated longer than CPK-MB. However, its prolonged elevation limits its utility in reinfarction detection, where CPK-MB’s shorter half-life is advantageous.
**Why the Correct Answer is Right**
In reinfarction, **Troponin-T remains elevated for 5–1